Kazakhstan to test first AI-designed COVID-19 vaccine in 2026
This digest was compiled by AI from multiple sources — links to the originals are below.
Kazakhstan plans to begin clinical trials of the world's first artificial intelligence-designed COVID-19 vaccine in 2026. The vaccine, developed by local researchers using AI platforms, targets new variants. The trials will involve 3,000 volunteers across three medical centers.
AI-Driven Development
The vaccine was designed by Kazakh scientists at the National Biotechnology Center using machine learning algorithms that analyzed over 100,000 viral protein structures. The AI identified conserved epitopes across SARS-CoV-2 variants, including Omicron sublineages. Development took 14 months, compared to the typical 3-5 years for conventional vaccines.
Trial Design and Timeline
Phase I trials are scheduled for Q1 2026 at clinics in Nur-Sultan, Almaty, and Shymkent. The study will test safety and immunogenicity in 3,000 healthy adults aged 18-65. Results are expected by Q3 2026, with Phase II planned for early 2027 if successful.
Global Context
No AI-designed vaccine has yet received regulatory approval worldwide. The World Health Organization has not issued guidelines for AI-developed biologics. Kazakhstan's Ministry of Health stated it will follow international standards for emergency use authorization.
What's Next
The Ministry of Health is set to approve the final trial protocol by September 2025. It remains unclear whether international regulators will accept AI-generated efficacy data without traditional preclinical models.
2 sources
Kazakhstan to test first AI-designed COVID-19 vaccine in 2026
